Entrar/Registro  
INICIO ENGLISH
 
Revista Mexicana de Neurociencia
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Revista Mexicana de Neurociencia >Año 2018, No. 4


Choreño-Parra JA, Carnalla-Cortés M, Martínez-Zúñiga N, Guadarrama-Ortíz P
Anticuerpos monoclonales contra el CGRP para el tratamiento de la migraña crónica y episódica
Rev Mex Neuroci 2018; 19 (4)

Idioma: Español
Referencias bibliográficas: 58
Paginas: 45-61
Archivo PDF: 569.34 Kb.


Texto completo




RESUMEN

La migraña es una condición clínica que provoca discapacidad en un porcentaje alto de la población económicamente activa. Este padecimiento se caracteriza por una cefalea unilateral pulsátil acompañada de otros fenómenos neurovasculares. La enfermedad puede adquirir un comportamiento crónico que obliga al paciente a recibir un tratamiento preventivo por un largo periodo de tiempo. Sin embargo, muchos fármacos hoy disponibles para dicho propósito causan diferentes efectos adversos que limitan su uso y la mayoría de ellos no fueron diseñados específicamente para la prevención de la migraña. La evidencia de la participación del péptido relacionado con el gen de la calcitonina (CGRP) en los mecanismos de sensibilización central al dolor y en la fisiopatología de la migraña ha llevado al desarrollo de tratamientos dirigidos a limitar su actividad biológica, entre los que se encuentran cuatro nuevos anticuerpos monoclonales contra dicha molécula o su receptor. Los ensayos clínicos hasta ahora realizados con estos anticuerpos aportan evidencia a favor de su empleo en el tratamiento y control de la migraña, por lo que en esta revisión se discuten los resultados de dichos estudios y se proveen las bases fisiológicas y moleculares que sustentan el uso del CGRP como blanco terapéutico.


Palabras clave: Péptido relacionado con el gen de la calcitonina, migraña, anticuerpos monoclonales, cefalea.


REFERENCIAS

  1. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016; 388 (10053): 1545-1602.

  2. Headache Classification Committee of the International Headache Society (HIS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018; 38 (1): 1-211.

  3. Manack AN, Buse DC, Lipton RB. Chronic migraine: epidemiology and disease burden. Curr Pain Headache Rep. 2011; 15 (1): 70-78.

  4. Stewart WF, Wood GC, Manack A, Varon SF, Buse DC, Lipton RB. Employment and work impact of chronic migraine and episodic migraine. J Occup Environ Med. 2010; 52 (1): 8-14.

  5. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007; 68 (5): 343-349.

  6. Martelletti P. The therapeutic armamentarium in migraine is quite elderly. Expert Opin Drug Metab Toxicol. 2015;11 (2):175-177.

  7. Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the Second International Burden of Migraine Study (IBMS-II). Headache. 2013; 53 (4): 644-655.

  8. Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015; 35 (6): 478-488.

  9. Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010; 30 (7): 793-803.

  10. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010; 30 (7): 804-814.

  11. Negro A, Curto M, Lionetto L, Giamberardino MA, Martelletti P. Chronic migraine treatment: from OnabotulinumtoxinA onwards. Expert Rev Neurother. 2016; 16 (10): 1217-1227.

  12. Edvinsson L. Functional role of perivascular peptides in the control of cerebral circulation. Trends Neurosci. 1985; 8: 126-131.

  13. Charles A. Migraine is not primarily a vascular disorder. Cephalalgia. 2012; 32 (5): 431-432.

  14. Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med. 2002; 8 (2): 136-142.

  15. Lambert GA. The lack of peripheral pathology in migraine headache. Headache. 2010; 50 (5): 895-908.

  16. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990; 28 (2): 183-187.

  17. Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010; 6 (10): 573-582.

  18. Poyner DR. Molecular pharmacology of receptors for calcitonin-gene-related peptide, amylin and adrenomedullin. Biochem Soc Trans. 1997; 25 (3): 1032-136.

  19. Maggi CA. Tachykinins and calcitonin gene-related peptide (CGRP) as co-transmitters released from peripheral endings of sensory nerves. Prog Neurobiol. 1995; 45 (1): 1-98.

  20. Muddhrry PK, Ghatki MA, Spokks RA, Jonhs PM, Pierson AM, Hamid QA, et al. Differential expression of alpha-CGRP and beta CGRP by primary sensory neurons and enteric autonomic neurons on the rat. Neuroscience. 1988; 25 (1): 195-205.

  21. Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev. 2002; 54 (2): 233-246.

  22. Brain SD, Williams TJ, Tippins JR, Morris HR, Macintyre I. Calcitonin gene-related peptide is a potent vasodilator. Nature. 1985; 313 (5997): 54-56.

  23. Summ O, Charbit AR, Andreou AP, Goadsby PJ. Modulation of nocioceptive transmission with calcitonin gene-related peptide receptor antagonists in the thalamus. Brain. 2010; 133 (9): 2540-2548.

  24. Marvizón JCG, Pérez OA, Song B, Chen W, Bunnett NW, Grady EF, et al. Calcitonin receptor-like receptor and receptor activity modifying protein 1 in the rat dorsal horn: localization in glutamatergic presynaptic terminals containing opioids and adrenergic α2C receptors. Neuroscience. 2007; 148 (1): 250-265.

  25. Marquez de Prado B, Hammond DL, Russo AF. Genetic enhancement of calcitonin gene-related peptideinduced central sensitization to mechanical stimuli in mice. J Pain. 2009; 10 (9): 992-1000.

  26. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia. 2002; 22 (1):54-61.

  27. Hansen JM, Hauge AW, Olesen J, Ashina M. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia. 2010; 30 (10): 1179-1186.

  28. Stepień A, Jagustyn P, Trafny EA, Widerkiewicz K. Suppressing effect of the serotonin 5HT1B/D receptor agonist rizatriptan on calcitonin gene-related peptide (CGRP) concentration in migraine attacks. Neurol Neurochir Pol. 2003; 37 (5):1013-1023.

  29. Cernuda-Morollón E, Larrosa D, Ramón C, Vega J, Martínez-Camblor P, Pascual J. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. 2013; 81 (14): 1191-1196.

  30. Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, et al. Calcitonin gene–related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004; 350 (11): 1104- 1110.

  31. Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008; 70(16): 1304-1312

  32. Connor KM, Shapiro RE, Diener HC, Lucas S, Kost J, Fan X, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology. 2009; 73 (12): 970-977.

  33. Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008; 372 (9656): 2115-2123.

  34. Connor KM, Aurora SK, Loeys T, Ashina M, Jones C, Giezek H, et al. Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial. Headache. 2011; 51 (1): 73-84.

  35. Ho TW, Connor KM, Zhang Y, Pearlman E, Koppenhaver J, Fan X, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology. 2014; 83 (11): 958-966.

  36. Russo FE. Calcitonin Gene-Related Peptide (CGRP): A New Target for Migraine. Annu Rev Pharmacol Toxicol. 2015; 55: 533-352.

  37. Hong P, Wu X, Liu Y. Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: a meta-analysis. Clin Neurol Neurosurg. 2017; 154: 74-78.

  38. Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med. 2017; 377 (22): 2113-2122.

  39. Walter S, Bigal ME. TEV-48125: a review of a monoclonal CGRP antibody in development for the preventive treatment of migraine. Curr Pain Headache Rep. 2015; 19 (3): 6.

  40. Bigal ME, Walter S, Bronson M, Alibhoy A, Escandon R. Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP. Cephalalgia. 2014; 34 (12): 968-76.

  41. Bigal ME, Escandon R, Bronson M, Walter S, Sudworth M, Huggins JP, et al. Safety and tolerability of LBR- 101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program. Cephalalgia. 2014; 34 (7): 483-92.

  42. Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings EL, Diener HC, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015; 14 (11): 1091-1100.

  43. Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, doubleblind, placebo-controlled, phase 2b study. Lancet Neurol. 2015; 14 (11): 1081-1090.

  44. Benschop RJ, Collins EC, Darling RJ, Allan BW, Leung D, Conner EM, et al. Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain. Osteoarthritis Cartilage. 2014; 22 (4): 578-585.

  45. Vermeersch S, Benschop RJ, Van Hecken A, Monteith D, Wroblewski VJ, Grayzel D, et al. Translational Pharmacodynamics of Calcitonin Gene-Related Peptide Monoclonal Antibody LY2951742 in a Capsaicin- Induced Dermal Blood Flow Model. J Pharmacol Exp Ther. 2015; 354 (3): 350-357.

  46. Monteith D, Collins EC, Vandermeulen C, Van Hecken A, Raddad E, Scherer JC, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers. Front Pharmacol. 2017; 8: 740.

  47. Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2014; 13 (9): 885-892.

  48. Skljarevski V, Oakes TM, Zhang Q, Ferguson MB, Martinez J, Camporeale A, et al. Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial. JAMA Neurol. 2018; 75 (2): 187-193.

  49. Baker B, Schaeffler B, Pederson S, Potter T, Smith J. A multiple-dose, placebo-controlled, randomized phase I clinical trial of ALD403, an anti-calcitonin gene-related peptide monoclonal antibody, administered once every 3-months via IV, SC, or IM. 58th Annual Scientific Meeting of the American Headache Society; June 2016, San Diego, California.

  50. Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomized, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014; 13 (11): 1100-1107.

  51. Saper J, Lipton R, Kudrow D, Hirman J, Dodick D, Silberstein S, et al. Primary Results of PROMISE-1 (Prevention Of Migraine via Intravenous eptinezumab Safety and Efficacy–1) Trial: a Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab for Prevention of Frequent Episodic Migraines. Neurology. 2018; 90 (15 Supplement): S20.001.

  52. de Hoon J, Van Hecken A, Vandermeulen C, Yan L, Smith B, Chen JS, et al. Phase I, randomized, doubleblind, placebo-controlled, single-dose, and multiple-dose studies of erenumab in healthy subjects and patients with migraine. Clin Pharmacol Ther. 2018; 103 (5): 815-825.

  53. Vu T, Ma P, Chen JS, de Hoon J, Van Hecken A, Yan L, et al. Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects. Pharm Res. 2017; 34 (9): 1784-1795.

  54. Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomized, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016 Apr;15 (4):382-390.

  55. Tepper S, Ashina M, Reuter U, Brandes JL, Colezil D, Silberstein S, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomized, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16 (6):425-434.

  56. Goadsby PJ, Reuter U, Hallstrom Y, Broessner G, Bonner JH, Zhang F, et al. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med. 2017; 377 (22): 2123-2132.

  57. Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018; 38 (6): 1026-1037.

  58. Baral P, Umans BD, Li L, Wallrapp A, Bist M, Kirschbaum T, et al. Nociceptor sensory neurons suppress neutrophil and γδ T cell responses in bacterial lung infections and lethal pneumonia. Nat Med. 2018 May;24 (4):417-426.



>Revistas >Revista Mexicana de Neurociencia >Año2018, No. 4
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019